Antibodies
28 September 2015
Synthon Reports Promising Initial Results from Phase I Trial with Anti-HER2 ADC SYD98528 September 2015
Lilly’s CYRAMZA® (ramucirumab) Significantly Improves Progression-Free Survival in Phase II Bladder Cancer Trial28 September 2015
New Data from KEYNOTE-028, Merck’s Trial Evaluating KEYTRUDA® (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress28 September 2015
Opdivo (nivolumab) Demonstrates Long Term Survival Benefit in Patients with Previously Treated Non-Squamous Non-Small Cell Lung Cancer in CheckMate -05728 September 2015
Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union28 September 2015
Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large Phase III Study26 September 2015
New Findings Show Anti-Tumor Activity of KEYTRUDA® (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma25 September 2015
Bayer’s Eye Drug Recommended for EU Approval in Fifth Indication25 September 2015
Amgen Receives CHMP Positive Opinions For Two New Treatment Options For Patients With Blood Cancer In Europe25 September 2015
CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)25 September 2015
Janssen’s daratumumab accepted for accelerated CHMP assessment for treatment of European patients with heavily pre-treated multiple myeloma25 September 2015
Biogen and Sobi Receive Positive Opinion from CHMP for ELOCTA™ (rFVIIIFc) for the Treatment of Hemophilia A24 September 2015
Xencor’s Partner Initiates Phase 2 Clinical Trial of a Biologic Candidate Using XmAb® Cytotoxic Fc Domain24 September 2015
Enumeral Announces Identification of Anti-PD-1 Antibodies with Potential for Differentiated Mechanism of Action24 September 2015
AstraZeneca presents advances in oncology research at ECC 2015 with data on AZD9291, durvalumab and LYNPARZA™ (olaparib)23 September 2015
Amgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 21523 September 2015
MorphoSys Publishes Update on MOR202 in Multiple Myeloma at 15th International Myeloma Workshop23 September 2015
RuiYi Announces the First Human Dosing of a Novel Antibody, Gerilimzumab, for the Treatment of Rheumatoid Arthritis and other Autoimmune Disorders22 September 2015
Pieris Pharmaceuticals Presents Positive Preclinical Data on Lead Bispecific Immuno-Oncology Program21 September 2015
First Marketing Authorizations in Europe for IQYMUNE®, LFB’s 10% Liquid Intravenous Immunoglobulin21 September 2015
BioInvent and the University of Pennsylvania enhance planned clinical study with BI-50521 September 2015
Pivotal Phase 3 Studies of Bezlotoxumab, Merck’s Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint17 September 2015
OncoMed Presents Immuno-Oncology Data for GITRL-Fc Candidate at the Inaugural International Cancer Immunotherapy ConferenceNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports